Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
HYPER-CVAD regimen
Introduction
Synonyms and keywords: Hyper-Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone regimen
Overview
Overview
HYPER-CVAD regimen refers to a regimen consisting of cyclophosphamide, vincristine, doxorubicin (Adriamycin), and dexamethasone used to treat some forms of Burkitt’s lymphoma, diffuse large B-cell lymphoma, and multiple myeloma.[1][2][3]
Regimen
Regimen
CCyclophosphamide
VVincristine (Oncovin)
ADoxorubicin (Adriamycin)
DDexamethasone
References
References
- ↑ 1.0 1.1 Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N; et al. (2012). “Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results”. Haematologica. 97 (3): 442–50. doi:10.3324/haematol.2011.043372. PMC 3291601. PMID 22058209.
- ↑ 2.0 2.1 Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S; et al. (2013). “Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma”. Br J Haematol. 163 (5): 611–20. doi:10.1111/bjh.12585. PMID 24117234.
- ↑ 3.0 3.1 Thomas DA, Faderl S, O’Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G; et al. (2006). “Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia”. Cancer. 106 (7): 1569–80. doi:10.1002/cncr.21776. PMID 16502413.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]